Search Results for "chemotherapy renewal"

“Sometimes you think, ‘Oh, these are just bladder patients; it’s different.’ But it might not be different. They still have a cancer diagnosis; this is still going to be a very fearful and unsettling time for that patient and their caregivers,” Tiffany Kurtz, MSN, RN, OCN®, manager of outpatient oncology at Summa Health Cancer Institute in Akron, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, oncology clinical specialist at ONS. Kurtz discussed intravesical administration and oncology nurses’ role in the treatment. You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.

Hazardous drugs are not just used in oncology, and their health risks for providers go far beyond reproductive toxicities. ONS member MiKaela Olsen, DNP, APRN-CNS, AOCNS^®, FAAN, clinical program director in oncology at the Johns Hopkins Hospital and Johns Hopkins Health System in Baltimore, MD, talks with Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, about protecting yourself and your colleagues with the latest updates in hazardous drug safety, including a change for the process of doffing personal protective equipment (PPE).

“A couple of things I think are really important when you look at this class of drug: It developed by a concerted effort in cancer drug development to look at new agents that would be effective based on the mechanism. And then once they found a drug in this class that was beneficial, they further modified it to try to get better efficacy and less toxicity,” Rowena “Moe” Schwartz, PharmD, BCOP, FHOPA, professor of pharmacy practice at James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS^®, manager of oncology nursing practice at ONS, during a conversation about the nitrosoureas drug class.

This short, patient-friendly video provides a general overview of how chemotherapy, targeted therapy, and immunotherapy work differently to treat cancer. This can be used to compliment your patient education and uses an analogy that is easy for patients to understand.

Lisa Kennedy-Sheldon, PhD, ANP-BC, AOCNP^®, FAAN, ONS clinical and scientific affairs liaison, joins Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS^®, ONS oncology clinical specialist and former home care nurse, to discuss how the COVID-19 coronavirus pandemic affects antineoplastics administration and safety considerations for in-home cancer care. More information is available in ONS’s recent position statement, linked in the episode notes.

This episode is supported by an educational grant from Genentech, a member of the Roche Group. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.

ONS member Diana Sutherland, MSN, AGNP-C, APRN, OCN^®, nurse practitioner at the UC Health Barrett Cancer Center in Cincinnati, OH, and member of the Cincinnati Tri-State ONS Chapter, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss how oncology nurses can safely administer trastuzumab chemotherapy and manage its associated side effects. This episode is part of an ongoing series about outpatient oncology drug infusion. The others are linked in the episode notes.